T1	intervention 0 9	Denosumab
T2	control 24 39	zoledronic acid
T3	condition 61 76	bone metastases
T4	eligibility 373 421	patients with breast cancer with bone metastases
T5	intervention-participants 532 537	1,026
T6	control-participants 639 644	1,020
T7	outcome-Measure 775 801	time to first on-study SRE
T8	outcome 948 974	time to first on-study SRE
T9	outcome 1149 1183	Reduction in bone turnover markers
T11	outcome 1343 1352	renal AEs
T12	outcome 1357 1378	acute-phase reactions
T13	outcome 1410 1422	hypocalcemia
T14	outcome 1464 1488	Osteonecrosis of the jaw
T15	iv-bin-percent 1512 1516	2.0%
T16	cv-bin-percent 1529 1533	1.4%
T17	outcome 1607 1634	delaying or preventing SREs
T10	outcome 1212 1228	Overall survival
T18	outcome 1230 1249	disease progression
T19	outcome 1264 1284	adverse events (AEs)
T20	outcome 1289 1300	serious AEs
